ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
